Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

2seventy bio, Inc. (NASDAQ:TSVT) COO Jessica Snow sold 2,298 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $11,375.10. Following the completion of the sale, the chief operating officer now directly owns 254,193 shares in the company, valued at approximately $1,258,255.35. The trade was a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

2seventy bio Stock Performance

Shares of NASDAQ:TSVT opened at $4.95 on Friday. The company has a market cap of $255.36 million, a P/E ratio of -2.66 and a beta of 1.73. 2seventy bio, Inc. has a one year low of $2.29 and a one year high of $5.99. The business’s 50-day simple moving average is $2.94 and its 200 day simple moving average is $3.71.

Institutional Investors Weigh In On 2seventy bio

Hedge funds have recently modified their holdings of the stock. BBR Partners LLC raised its holdings in shares of 2seventy bio by 620.0% during the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after buying an additional 155,000 shares during the period. Rhumbline Advisers raised its holdings in shares of 2seventy bio by 9.5% during the 4th quarter. Rhumbline Advisers now owns 84,670 shares of the company’s stock valued at $249,000 after buying an additional 7,379 shares during the period. Geode Capital Management LLC increased its holdings in 2seventy bio by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock worth $5,553,000 after purchasing an additional 13,144 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in 2seventy bio during the 3rd quarter worth approximately $64,000. Finally, FMR LLC increased its holdings in 2seventy bio by 22.0% during the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock worth $701,000 after purchasing an additional 26,738 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TSVT. Leerink Partners reaffirmed a “market perform” rating and issued a $5.00 price objective (down from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 2seventy bio in a research note on Friday, March 7th. Morgan Stanley reduced their price objective on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Friday, March 14th. Finally, Leerink Partnrs lowered 2seventy bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $6.67.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.